Should I buy or sell AxoGen stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares. View AXGN analyst ratings or view top-rated stocks .

What is AxoGen's stock price target for 2024?

4 brokers have issued twelve-month price objectives for AxoGen's stock. Their AXGN share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 109.8% from the stock's current price. View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts .

How have AXGN shares performed in 2023?

AxoGen's stock was trading at $9.98 at the beginning of 2023. Since then, AXGN stock has decreased by 28.4% and is now trading at $7.15. View the best growth stocks for 2023 here .

Are investors shorting AxoGen?

AxoGen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, an increase of 33.3% from the October 31st total of 1,620,000 shares. Based on an average trading volume of 433,100 shares, the days-to-cover ratio is presently 5.0 days. Currently, 5.3% of the company's stock are sold short. View AxoGen's Short Interest .

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our AXGN earnings forecast .

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) announced its earnings results on Tuesday, November, 7th. The medical equipment provider reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.08. The medical equipment provider earned $41.27 million during the quarter, compared to the consensus estimate of $40 million. AxoGen had a negative trailing twelve-month return on equity of 23.44% and a negative net margin of 15.26%.

What ETF holds AxoGen's stock ?

iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com . Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD) , Bank of America (BAC) , Intelsat (I) , Intel (INTC) , Micron Technology (MU) , Xilinx (XLNX) , Corbus Pharmaceuticals (CRBP) , Exelixis (EXEL) , NVIDIA (NVDA) and Fossil Group (FOSL) .

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Tocqueville Asset Management L.P. (2.18%), Northern Trust Corp (0.94%), Ameriprise Financial Inc. (0.69%), Essex Investment Management Co. LLC (0.69%), Legal & General Group Plc (0.43%) and Acadian Asset Management LLC (0.42%). Insiders that own company stock include Amy Mcbride Wendell, Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Karen L Zaderej, Karen L Zaderej , Maria D Martinez , Michael Patrick Donovan , Peter J Mariani and William P Mr Burke. View institutional ownership trends .

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

AxoGen Stock Price, News & Analysis (NASDAQ:AXGN)

$7.15

+0.27 (+3.92%)

(As of 12/4/2023 ET)

Compare

Today's Range: $6.83
▼
$7.17
50-Day Range: $3.61
▼
$6.88
52-Week Range: $3.45
▼
$11.32

Volume: 304,815 shs
Average Volume: 299,316 shs
Market Capitalization: $307.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

AxoGen MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 109.8% Upside
$15.00 Price Target
Short Interest: Bearish
5.33% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$62,200 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.58) to ($0.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

471st out of 952 stocks

Medical Devices Industry

3rd out of 9 stocks

3.5

Analyst's Opinion

Consensus Rating
AxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, AxoGen has a forecasted upside of 109.8% from its current price of $7.15.
Amount of Analyst Coverage
AxoGen has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.33% of the float of AxoGen has been sold short.
Short Interest Ratio / Days to Cover
AxoGen has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in AxoGen has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
AxoGen does not currently pay a dividend.
Dividend Growth
AxoGen does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AXGN.

3.1

News and Social Media Coverage

News Sentiment
AxoGen has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for AxoGen this week, compared to 1 article on an average week.
Search Interest
2 people have searched for AXGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
3 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AxoGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $62,200.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.21% of the stock of AxoGen is held by insiders.
Percentage Held by Institutions
83.77% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AxoGen are expected to grow in the coming year, from ($0.58) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AxoGen is -12.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AxoGen is -12.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AxoGen has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AxoGen Stock (NASDAQ:AXGN)

AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

AXGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AXGN Stock News Headlines

December 1, 2023 | finance.yahoo.com

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 1, 2023 | americanbankingnews.com

AxoGen, Inc. (NASDAQ:AXGN) Sees Large Increase in Short Interest

December 5, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 29, 2023 | americanbankingnews.com

AxoGen (NASDAQ:AXGN) Lowered to "Hold" at StockNews.com

November 20, 2023 | finance.yahoo.com

Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference

November 17, 2023 | finance.yahoo.com

Great week for AxoGen, Inc. (NASDAQ:AXGN) institutional investors after losing 51% over the previous year

November 9, 2023 | morningstar.com

Axogen Inc AXGN

November 8, 2023 | marketwatch.com

Axogen Shares Rise 34% After Narrower-Than-Expected 3Q Loss

December 5, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

November 8, 2023 | finance.yahoo.com

AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Call Transcript

November 7, 2023 | finance.yahoo.com

Axogen, Inc. Reports 2023 Third Quarter Financial Results

November 7, 2023 | finance.yahoo.com

Axogen Inc (AXGN) Reports 12% Revenue Growth in Q3 2023

November 6, 2023 | msn.com

AxoGen Q3 2023 Earnings Preview

October 18, 2023 | finance.yahoo.com

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

October 17, 2023 | msn.com

Leerink Partners Initiates Coverage of Axogen (AXGN) with Outperform Recommendation

September 28, 2023 | finance.yahoo.com

AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?

September 5, 2023 | finance.yahoo.com

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

August 23, 2023 | msn.com

Cantor Fitzgerald Reiterates Axogen (AXGN) Overweight Recommendation

August 21, 2023 | finance.yahoo.com

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

August 10, 2023 | finance.yahoo.com

AxoGen, Inc. (NASDAQ:AXGN) Q2 2023 Earnings Call Transcript

August 8, 2023 | markets.businessinsider.com

JMP Securities Remains a Buy on AxoGen (AXGN)

August 8, 2023 | finance.yahoo.com

Axogen, Inc. Reports 2023 Second Quarter Financial Results

August 8, 2023 | finance.yahoo.com

AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates

July 27, 2023 | finance.yahoo.com

Axogen to Participate at Canaccord Genuity’s 43rd Annual Growth Conference

July 26, 2023 | finance.yahoo.com

Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023

July 5, 2023 | fool.com

AxoGen (NASDAQ: AXGN)

June 10, 2023 | finance.yahoo.com

With 71% ownership, AxoGen, Inc. (NASDAQ:AXGN) boasts of strong institutional backing

See More Headlines

Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical Devices
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AXGN
CUSIP: N/A
CIK: 805928
Web: www.axogeninc.com
Phone: (386) 462-6800
Fax: 386-462-6801
Employees: 394
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $20.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +109.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,950,000.00
Net Margins: -15.26%
Pretax Margin: -15.26%
Return on Equity: -23.44%
Return on Assets: -11.96%

Debt

Debt-to-Equity Ratio: 0.68
Current Ratio: 3.28
Quick Ratio: 2.42

Sales & Book Value

Annual Sales: $138.58 million
Price / Sales: 2.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.39 per share
Price / Book: 2.99

Miscellaneous

Outstanding Shares: 43,040,000
Free Float: 39,941,000
Market Cap: $307.74 million
Optionable: Optionable
Beta: 1.12

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Ms. Karen Zaderej (Age 61)
Chairman, President & CEO
Comp: $852.18k
Mr. Peter J. Mariani (Age 59)
Executive VP & CFO
Comp: $532.5k
Mr. Michael Donovan (Age 58)
Vice President of Operations
Comp: $406.02k
Mr. Angelo G. Scopelianos Ph.D. (Age 68)
Chief Research & Development Officer
Comp: $540.91k
Ed Joyce
Director of Investor Relations
Mr. Marc A. Began (Age 55)
Executive VP, General Counsel & Chief Compliance Officer
Ms. Doris Quackenbush
Vice President of Sales
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Mr. Erick DeVinney (Age 47)
Vice President of Peripheral Nerve Science and Clinical Innovation

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXGN Stock Analysis - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings or view top-rated stocks.
What is AxoGen's stock price target for 2024?: 4 brokers have issued twelve-month price objectives for AxoGen's stock. Their AXGN share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 109.8% from the stock's current price.
View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts.
How have AXGN shares performed in 2023?: AxoGen's stock was trading at $9.98 at the beginning of 2023. Since then, AXGN stock has decreased by 28.4% and is now trading at $7.15.
View the best growth stocks for 2023 here.
Are investors shorting AxoGen?: AxoGen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, an increase of 33.3% from the October 31st total of 1,620,000 shares. Based on an average trading volume of 433,100 shares, the days-to-cover ratio is presently 5.0 days. Currently, 5.3% of the company's stock are sold short.
View AxoGen's Short Interest.
When is AxoGen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our AXGN earnings forecast.
How were AxoGen's earnings last quarter?: AxoGen, Inc. (NASDAQ:AXGN) announced its earnings results on Tuesday, November, 7th. The medical equipment provider reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.08. The medical equipment provider earned $41.27 million during the quarter, compared to the consensus estimate of $40 million. AxoGen had a negative trailing twelve-month return on equity of 23.44% and a negative net margin of 15.26%.

What ETF holds AxoGen's stock ?: iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio.
What is Karen Zaderej's approval rating as AxoGen's CEO?: 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.
What other stocks do shareholders of AxoGen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).
Who are AxoGen's major shareholders?: AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Tocqueville Asset Management L.P. (2.18%), Northern Trust Corp (0.94%), Ameriprise Financial Inc. (0.69%), Essex Investment Management Co. LLC (0.69%), Legal & General Group Plc (0.43%) and Acadian Asset Management LLC (0.42%). Insiders that own company stock include Amy Mcbride Wendell, Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke.
View institutional ownership trends.
How do I buy shares of AxoGen?: Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AXGN) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial